Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 35 for your search:

Drug:  keyhole limpet hemocyanin
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1694, CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9

Phase III Multicenter, Randomized, Controlled Study of THERATOPE Vaccine in Women With Metastatic Breast Cancer (Summary Last Modified 05/2001)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BIOMIRA-STn-BR-104, NCI-V98-1489, NCT00003638

Phase III Randomized Study of BCI-ImmuneActivator™ (Keyhole Limpet Hemocyanin) Versus Doxorubicin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer

Phase: Phase III
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INTRACEL-BCI-9804-04, NCT00006034

Phase III Randomized Study of Cyclophosphamide, Prednisone, and Vincristine Followed By Immunotherapy With Keyhole Limpet Hemocyanin With or Without Recombinant Autologous Tumor-Derived Immunoglobulin Idiotype and Adjuvant Sargramostim (GM-CSF) in Patients With Stage III or IV Follicular B-Cell Non-Hodgkin's Lymphoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENITOPE-G2000-03, CUMC-0101-142, UCLA-0010061, NCT00017290

Phase I/II Pilot Study of Anti-Idiotypic MOAB BEC2 Conjugated to KLH plus BCG as Adjuvant in Completely Resected Melanoma (Summary Last Modified 03/95)

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-94078, NCI-H94-0538

Phase I/II Study of Purified Myeloma Protein Immunization in Sibling Peripheral Blood Stem Cell (PBSC) Donors and in Patients With Multiple Myeloma Who Are Undergoing Nonmyeloablative Chemotherapy and HLA-Matched Allogeneic PBSC Transplantation

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: NCI
Protocol IDs: NCI-00-C-0201, NCI-1029, 1029, NCT00020306

Phase I/II Randomized Study of Vaccination With Melanoma Antigen-Pulsed Dendritic Cells Versus Melanoma Antigens With QS21 Adjuvant in Patients With Surgically Resected Stage IIB, IIC, or III Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYU-RUH-NBH-0428-0401, RUH-NBH-0428-0401, NCI-5636, NCT00045383, 5636

Phase II Study of Tumor-Derived Immunoglobulin Idiotype Vaccination and Sargramostim following Cyclophosphamide/Doxorubicin/Etoposide/Prednisone in Low-Grade Follicular Lymphoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-96-C-0133, CRB-9309, NCI-T93-0164N, T93-0164, NCT00878488

Phase II Randomized, Double-Blind Study of 3 Doses of Sialyl Tn-KLH Therapeutic Vaccine with Detox B Adjuvant as Active-Specific Immunotherapy for Colorectal Cancer (Summary Last Modified 05/98)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: UNMC-04094, NCI-V94-0589

10.

Phase II Study of Active Immunization of Related Bone Marrow Transplant Donors Against Purified Myeloma Protein from the Recipient Undergoing Allogeneic Bone Marrow Transplantation

Phase: Phase II
Type: Treatment
Status: Completed
Age: under 60
Sponsor: NCI
Protocol IDs: NCI-97-C-0030B, CRB-9407, NCI-T94-0085N, T94-0085

11.

Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-97-C-0033B, CRB-9409, NCI-T94-0094N, T94-0094, NCT00019097

12.

Phase II Study of Allogeneic T-Cell-Depleted BMT, Followed by Transplantation of Allogeneic T Cells from Idiotype-Vaccinated Donors, for Multiple Myeloma (Summary Last Modified 04/98)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI, NHLBI
Protocol IDs: NHLBI-T96-0017, NCI-T96-0017N, T96-0017

13.

Phase II Study of Vaccination with Tn(c)-KLH Conjugate Plus the Immunological Adjuvant QS21 in Patients with Prostate Cancer (Summary Last Modified 05/1999)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98002, NCI-G98-1440

14.

Phase II Study of Adjuvant Immunotherapy With Recombinant Tumor Derived Immunoglobulin Idiotype With Keyhole Limpet Hemocyanin Conjugate Plus Sargramostim (GM-CSF) Following Chemotherapy in Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: UNMC-197-99, GENITOPE-9902, SUMC-9902, NCT00004197

15.

Phase II Study of Adjuvant Immunotherapy With Recombinant Tumor Derived Immunoglobulin Idiotype With Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) Following Chemotherapy in Patients With Previously Untreated Stage III or IV Indolent Follicular Non-Hodgkin's Lymphoma (Summary Last Modified 03/2001)

Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: UNMC-196-99, GENITOPE-9901, NCT00004198

16.

Phase II Study of Immunization With Polysialic Acid Keyhole Limpet Hemocyanin (PSA-KLH) Conjugate or N-Propionylated PSA-KLH Hemocyanin Conjugate Plus Immunological Adjuvant QS21 in Patients With Small Cell Lung Cancer With Complete or Partial Response to Initial Therapy

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98065, NCI-H99-0047, NCT00004249

17.

Phase II Pilot Study of Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) Followed By Immunotherapy With Autologous Tumor-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Previously Untreated Mantle Cell Lymphoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-00-C-0133, NCI-1033, NCT00020215

18.

Phase II Pilot Study of Idiotype Vaccines Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation in Patients With Follicular Non-Hodgkin's Lymphoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 19
Sponsor: Pharmaceutical / Industry
Protocol IDs: UNMC-260-00, GENITOPE-IND-8294, NCT00006478

19.

Phase II Study of Autologous Tumor Cell Vaccine With Adjuvant Sargramostim (GM-CSF) in Patients With Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FAV-ID-01, SKCC-2001, SKCC-BB-IND-8786

20.

Phase II Pilot Adjuvant Study of Vaccination with Sialyl Tn Antigen Covalenty Attached to KLH plus Detox in Patients with High-Risk Resected Colorectal Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor:
Protocol IDs: MSKCC-91095, NCI-V91-0167

21.

Phase II Pilot Study of Vaccination with Sialyl Tn Antigen Covalently Attached to KLH plus QS21 in High-Risk Resected Colorectal Cancer (Summary Last Modified 07/95)

Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-92100, NCI-V92-0144

22.

Phase II Pilot Study of Vaccination with GD3 Covalently Attached to KLH plus the Immunological Adjuvant QS21 in Patients with Resected Stage III/IV Melanoma (Summary Last Modified 06/93)

Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-92168, NCI-V93-0228

23.

Phase II Pilot Study of Vaccination with GD2 Covalently Attached to KLH plus the Immunological Adjuvant QS21 in Patients with Resected High-Risk Stage III/IV Melanoma (Summary Last Modified 06/93)

Phase: Phase II
Type: Treatment
Status: Completed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-92169, NCI-V93-0229

24.

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 2000-46, NCT00083538

25.

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000389145, STLMC-IMM-03-05, STLMC-L-03-138, NCT00093522

Select All on Page

Help with Results

A Service of the National Cancer Institute